Icahn Wins Third Seat On Biogen Board

Mar 23 2010 | 12:20pm ET

To prevent a third proxy battle with Carl Icahn in three years, biotechnology company Biogen Idec has agreed to give the activist hedge fund manager a third seat on its board of directors.

Carl IcahnCarl IcahnUnder the deal with Icahn, cancer specialist Eric Rowinsky will join Biogen’s board, alongside Alexander Denner, managing director of Icahn Partners, and Harvard Medical School genetics professor Richard Mulligan, Icahn nominees elected to the board last year.

For his part, Icahn has agreed to withdraw his three nominees to the board this year and the hedge fund will vote its shares for the management slate.


In Depth

bfinance: Fees Falling Across Asset Classes, Yet Overall Investor Costs Still Climbing

May 16 2017 | 9:53pm ET

Despite unprecedented attention on fees, new research from investment consultancy...

Lifestyle

CFA Institute To Add Computer Science To Exam Curriculum

May 24 2017 | 9:25pm ET

Starting in 2019, financial industry executives sitting for the coveted Chartered...

Guest Contributor

Risk-Based Compliance: Why Oversight Of Outsourcing Is Critical

May 10 2017 | 7:02pm ET

Compliance is notoriously one of the trickiest middle office functions for funds...

 

From the current issue of